Biomarin Pharmaceutical Inc
BMRN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001048477
In the last 90 days, Biomarin Pharmaceutical Inc insiders filed 0 open-market purchases and 1 sale; 565 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; Viking Global Investors is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Biomarin Pharmaceutical Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $1.16M in total
- Insiders trading
- 1
- Net value
- −$1.16M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Biomarin Pharmaceutical Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Plenge Robert M | Director | 6,140 | Sep 14, 2026 | 1 |
| Davis George Eric | EVP, Chief Legal Officer | 61,003 | Sep 3, 2026 | 4 |
| Dere Willard H | Director | 46,440 | Jun 4, 2026 | 1 |
| Clark Ian T | Director | 14,490 | Jun 4, 2026 | 1 |
| Walbert Timothy P | Director | 17,270 | Jun 4, 2026 | 1 |
| Hombach Robert J. | Director | 49,360 | Jun 4, 2026 | 1 |
| Countouriotis Athena | Director | 21,040 | Jun 4, 2026 | 1 |
| Enyedy Mark J | Director | 21,040 | Jun 4, 2026 | 1 |
| Ho Maykin | Director | 35,500 | Jun 4, 2026 | 1 |
| Bodem Barbara W. | Director | 21,045 | Jun 4, 2026 | 1 |
| Anderson Elizabeth M | Director | 41,940 | Jun 4, 2026 | 1 |
| Hubbard Cristin | EVP, Chief Commercial Officer | 42,472 | May 21, 2026 | 2 |
| Friberg Gregory R | EVP, Chief R&D Officer | 51,818 | May 11, 2026 | 4 |
| Mueller Brian | EVP, Chief Financial Officer | 123,314 | Mar 19, 2026 | 3 |
| Guyer Charles Greg | EVP, Chief Technical Officer | 84,140 | Mar 19, 2026 | 4 |
| Hardy Alexander | Chief Executive Officer | 214,635 | Mar 19, 2026 | 3 |
| Ramchandani Rashmi Virendra | VP, Chief Accounting Officer | 25,610 | Jan 22, 2026 | 1 |
| Meier Richard A | Director | 127,426 | May 22, 2025 | 0 |
| Burkhart Erin | GVP, Chief Accounting Officer | 14,173 | May 20, 2025 | 0 |
| Fuchs Henry J | President, Worldwide R&D | 185,074 | Sep 17, 2024 | 0 |
| Heron Elaine J | Director | 97,720 | Jun 4, 2024 | 0 |
| Pyott David E I | Director | 49,750 | May 23, 2024 | 0 |
| Bienaime Jean Jacques | Director | 473,792 | May 21, 2024 | 0 |
| Ajer Jeffrey Robert | EVP, Chief Commercial Officer | 66,767 | May 6, 2024 | 0 |
| Slamon Dennis | Director | 31,299 | Mar 20, 2024 | 0 |
| Lawlis V Bryan | Director | 33,140 | May 24, 2023 | 0 |
| Alles Mark J | Director | 15,095 | May 24, 2023 | 0 |
| Acosta Andrea | GVP, Chief Accounting Officer | 18,122 | Jul 19, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2023 (view filing) | Aug 10 | 1 day | Fuchs Henry JPresident, Worldwide R&D | SSale | −12.0K | $90.43 | −$1.09M | −6.4%176.2K after | |
| Aug 17, 2023 (view filing) | Aug 16 | 1 day | Ajer Jeffrey RobertEVP, Chief Commercial Officer | SSale | −5.00K | $90.00 | −$450.0K | −7.6%60.8K after | 10b5-1 |
| Dec 14, 2023 (view filing) | Dec 13 | 1 day | Davis George EricEVP, Chief Legal Officer | SSale | −13.8K | $95.30 | −$1.31M | −19.8%55.7K after | 10b5-1 |
| Dec 22, 2023 (view filing) | Dec 21 | 1 day | Bienaime Jean JacquesDirector | SSale | −10.0K | $93.99 | −$939.9K | −2.3%425.1K after | 10b5-1 |
| Jan 11, 2024 (view filing) | Jan 9-10 | 2 days | Bienaime Jean JacquesDirector | SSale | −20.0K | $97.29 | −$1.95M | −4.5%425.2K after | 2 lots10b5-1 |
| Feb 12, 2024 (view filing) | Feb 8-9 | 4 days | Bienaime Jean JacquesDirector | SSale | −30.0K | $89.03 | −$2.67M | −6.7%419.6K after | 2 lots10b5-1 |
| Feb 29, 2024 (view filing) | Feb 27 | 2 days | Bienaime Jean JacquesDirector | SSale | −1.00K | $90.35 | −$90.3K | −0.2%562.2K after | |
| Mar 7, 2024 (view filing) | Mar 5 | 2 days | Ajer Jeffrey RobertEVP, Chief Commercial Officer | SSale | −4.00K | $87.07 | −$348.3K | −4.1%94.0K after | 10b5-1 |
| Mar 7, 2024 (view filing) | Mar 5-6 | 2 days | Bienaime Jean JacquesDirector | SSale | −2.00K | $86.11 | −$172.2K | −0.4%560.2K after | 2 lots |
| Mar 7, 2024 (view filing) | Mar 5 | 2 days | Fuchs Henry JPresident, Worldwide R&D | SSale | −35.3K | $85.18 | −$3.01M | −14.3%212.1K after | |
| Apr 1, 2024 (view filing) | Mar 28 | 4 days | Davis George EricEVP, Chief Legal Officer | SSale | −24.6K | $88.34 | −$2.17M | −30.6%55.9K after | 10b5-1 |
| Apr 12, 2024 (view filing) | Apr 10 | 2 days | Burkhart ErinGVP, Chief Accounting Officer | SSale | −2.29K | $90.00 | −$205.7K | −12.4%16.2K after | 10b5-1 |
| Apr 15, 2024 (view filing) | Apr 11-12 | 4 days | Bienaime Jean JacquesDirector | SSale | −40.0K | $91.13 | −$3.65M | −7.8%475.0K after | 2 lots10b5-1 |
| May 6, 2024 (view filing) | May 2 | 4 days | Ajer Jeffrey RobertEVP, Chief Commercial Officer | SSale | −5.00K | $82.91 | −$414.6K | −7.0%66.8K after | 10b5-1 |
| May 6, 2024 (view filing) | May 2 | 4 days | Davis George EricEVP, Chief Legal Officer | SSale | −1.85K | $85.01 | −$157.3K | −3.2%56.2K after | 10b5-1 |
| May 13, 2024 (view filing) | May 9-10 | 4 days | Bienaime Jean JacquesDirector | SSale | −40.0K | $81.38 | −$3.26M | −7.8%475.0K after | 2 lots10b5-1 |
| May 30, 2024 (view filing) | May 28 | 2 days | Davis George EricEVP, Chief Legal Officer | SSale | −40.9K | $74.52 | −$3.04M | −42.1%56.2K after | 2 lots10b5-1 |
| May 31, 2024 (view filing) | May 30 | 1 day | Mueller BrianEVP, Chief Financial Officer | SSale | −5.00K | $75.19 | −$375.9K | −6.5%72.2K after | 10b5-1 |
| Aug 15, 2024 (view filing) | Aug 13 | 2 days | Burkhart ErinGVP, Chief Accounting Officer | SSale | −714 | $90.00 | −$64.3K | −4.7%14.4K after | 10b5-1 |
| Nov 14, 2024 (view filing) | Nov 12 | 2 days | Guyer Charles GregEVP, Chief Technical Officer | SSale | −5.28K | $66.37 | −$350.3K | −7.1%68.9K after | |
| Feb 25, 2025 (view filing) | Feb 24 | 1 day | Burkhart ErinGVP, Chief Accounting Officer | SSale | −1.34K | $68.38 | −$91.9K | −9.3%13.1K after | 10b5-1 |
| Mar 7, 2025 (view filing) | Mar 6 | 1 day | Guyer Charles GregEVP, Chief Technical Officer | SSale | −7.03K | $71.28 | −$501.4K | −7.4%87.7K after | |
| Mar 20, 2025 (view filing) | Mar 19 | 1 day | Burkhart ErinGVP, Chief Accounting Officer | SSale | −1.29K | $71.52 | −$92.6K | −7.1%17.0K after | 10b5-1 |
| May 6, 2025 (view filing) | May 2 | 4 days | Hubbard CristinEVP, Chief Commercial Officer | SSale | −273 | $64.92 | −$17.7K | −0.8%32.7K after | 10b5-1 |
| May 20, 2025 (view filing) | May 20 | Same day | Burkhart ErinGVP, Chief Accounting Officer | SSale | −1.79K | $59.31 | −$105.9K | −11.2%14.2K after | 10b5-1 |
| Feb 26, 2026 (view filing) | Feb 26 | Same day | Davis George EricEVP, Chief Legal Officer | SSale | −26.1K | $61.36 | −$1.60M | −26.5%72.5K after | |
| Feb 26, 2026 (view filing) | Feb 26 | Same day | Friberg Gregory REVP, Chief R&D Officer | SSale | −6.33K | $60.38 | −$382.0K | −14.4%37.6K after | |
| Mar 12, 2026 (view filing) | Mar 11 | 1 day | Guyer Charles GregEVP, Chief Technical Officer | SSale | −16.5K | $60.46 | −$996.7K | −17.1%80.0K after | |
| May 11, 2026 (view filing) | May 7 | 4 days | Friberg Gregory REVP, Chief R&D Officer | SSale | −3.28K | $53.85 | −$176.7K | −6.0%51.8K after | |
| Sep 3, 2026 (view filing)6:41 PM ET | Sep 2 | 1 day | Davis George EricEVP, Chief Legal Officer | SSale | −17.6K | $66.28 | −$1.16M | −22.3%61.0K after |